X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.indianpharmapost.com/news/palatin-completes-sale-of-vyleesi-to-cosette-pharmaceuticals-for-up-to-171-mn-15086
https://www.prnewswire.com/news-releases/palatin-completes-sale-of-vyleesi-to-cosette-pharmaceuticals-for-up-to-171-million-302020026.html
https://www.prnewswire.com/news-releases/palatin-announces-preliminary-fourth-quarter-fiscal-2023-vyleesi-product-revenue-results-301873916.html
https://www.prnewswire.com/news-releases/palatin-issued-patent-on-vyleesi-bremelanotide-injection-for-hypoactive-sexual-desire-disorder-in-patients-with-controlled-hypertension-301757636.html
https://www.prnewswire.com/news-releases/palatin-initiates-enrollment-in-the-phase-2-bremelanotide-breakout-study-in-patients-with-diabetic-kidney-disease-301725239.html
https://www.prnewswire.com/news-releases/palatin-announces-preliminary-second-quarter-fiscal-2023-vyleesi-product-sales-results-301714221.html
https://www.prnewswire.com/news-releases/palatin-announces-publication-of-vyleesi-bremelanotide-fmri-study-in-women-with-hypoactive-sexual-desire-disorder-hsdd-301650502.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-27-2022-1651037135.pdf
https://www.prnewswire.com/news-releases/palatin-technologies-announces-mutual-termination-of-license-agreement-with-amag-pharmaceuticals-for-vyleesi-301099890.html
https://www.reuters.com/article/us-amag-divestiture/amag-pharmaceuticals-to-divest-two-womens-health-drugs-ceo-to-step-down-idUSKBN1Z81JX?feedType=RSS&feedName=healthNews
https://www.biospace.com/article/releases/vyleesi-phase-3-data-to-be-presented-at-the-13th-european-society-of-gynecology-congress/?s=95
https://www.fiercepharma.com/pharma/troubled-amag-spurns-activist-investor-s-attempt-to-rework-board-as-share-price-flags
https://endpts.com/embattled-amag-braces-for-october-fda-makena-adcom-but-it-need-not-worry-analyst/
https://www.reuters.com/article/us-amag-fda-pricing/amags-female-libido-injectable-therapy-to-sell-at-899-idUSKCN1UW1W0
https://www.biospace.com/article/how-the-pharmaceutical-industry-is-looking-to-treat-low-sex-drive/
https://www.fiercepharma.com/marketing/amag-wins-fda-nod-for-vyleesi-could-it-be-female-viagra-addyi-never-was
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210557
https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-orgs/documents/document/ucm628524.pdf
https://www.pharmacompass.com/pdf/news/fda-alerts-not-to-use-promise-pharmacys-drugs-intended-to-be-sterile-1544508007.pdf
https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/UCM626320.pdf
https://www.prnewswire.com/news-releases/palatin-technologies-announces-fda-acceptance-for-review-of-bremelanotide-nda-300658859.html
https://www.prnewswire.com/news-releases/palatin-announces-start-of-bremelanotide-phase-3-program-for-female-sexual-dysfunction-300014102.html
Market Place
Share 
